HTT and Huntington disease: Interestingly, Novartis has announced a finding of reduced huntingtin mRNA (the mutated protein in Huntington’s disease) in SMA patients treated with branaplam, which has formed the basis of the FDA’s Orphan Drug Designation for branaplam in Huntington’s disease, with a phase IIb trial planned in 2021.47